{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:29:04Z","timestamp":1767839344014,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.anai.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T03:31:36Z","timestamp":1521430296000},"page":"641-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Validity and responsiveness of the Urticaria Activity and Impact Measure"],"prefix":"10.1016","volume":"120","author":[{"given":"Marcus","family":"Maurer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan D.","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross D.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamina","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Zazzali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.03.012_bib0010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00130832-200310000-00008","article-title":"Chronic idiopathic urticaria","volume":"3","author":"Greaves","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria: a GA(2)LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.03.012_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.iac.2013.09.012","article-title":"Chronic spontaneous urticaria: etiology and pathogenesis","volume":"34","author":"Saini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2018.03.012_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.anai.2016.06.024","article-title":"Angioedema in the omalizumab chronic idiopathic\/spontaneous urticaria pivotal studies","volume":"117","author":"Zazzali","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0030","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.14075","article-title":"Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic\/spontaneous urticaria: analyses according to the presence or absence of angioedema","volume":"31","author":"Maurer","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2018.03.012_bib0035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/all.12870","article-title":"Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial","volume":"71","author":"Staubach","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.03.012_bib0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/all.13339","article-title":"Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data","volume":"73","author":"Staubach","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.03.012_bib0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1468-3083.2007.02324.x","article-title":"The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria","volume":"22","author":"Engin","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2018.03.012_bib0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1398-9995.2008.01853.x","article-title":"Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation","volume":"64","author":"Maurer","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.03.012_bib0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.iac.2013.09.011","article-title":"Urticaria: impact on quality of life and economic cost","volume":"34","author":"O'Donnell","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2018.03.012_bib0060","first-page":"897","article-title":"Quality of life assessment in patients with chronic urticaria","volume":"86","author":"Ue","year":"2011","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.anai.2018.03.012_bib0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archdermatol.2007.6","article-title":"Chronic idiopathic urticaria: a \u201cCinderella\u201d disease with a negative impact on quality of life and health care costs","volume":"144","author":"Yosipovitch","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.anai.2018.03.012_bib0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2010.06.011","article-title":"Development of a daily diary for patients with chronic idiopathic urticaria","volume":"105","author":"Mathias","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0075","first-page":"9","article-title":"Approach to therapy in chronic urticaria: when benadryl is not enough","volume":"26","author":"Tilles","year":"2005","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2018.03.012_bib0080","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0085","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.03.012_bib0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","article-title":"How to assess disease activity in patients with chronic urticaria?","volume":"63","author":"Mlynek","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.03.012_bib0095","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA(2) LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.03.012_bib0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/all.13271","article-title":"Comparison and interpretability of the available urticaria activity scores","volume":"73","author":"Hawro","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.03.012_bib0105","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/bjd.15454","article-title":"Analysis of disease activity categories in chronic spontaneous\/idiopathic urticaria","volume":"177","author":"Stull","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.03.012_bib0110","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","article-title":"The XTEND-CIU study: long term use of omalizumab in chronic idiopathic urticaria","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2017.10.010","article-title":"Omalizumab response in patients with chronic idiopathic urticaria: insights from the XTEND-CIU study","volume":"78","author":"Casale","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.03.012_bib0120","doi-asserted-by":"crossref","first-page":"AB271","DOI":"10.1016\/j.jaci.2016.12.874","article-title":"Study design, baseline and open-label results from XTEND-CIU: a phase IV, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab through 48 weeks in patients with chronic idiopathic urticaria","volume":"139","author":"Casale","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.anai.2018.03.012_bib0130","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.jaci.2017.04.050","article-title":"Responsiveness and minimal important difference of the urticaria control test","volume":"140","author":"Ohanyan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0135","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.03.012_bib0140","series-title":"Insomnia: Psychological Assessment and Manatement","author":"Morin","year":"1993"},{"key":"10.1016\/j.anai.2018.03.012_bib0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.anai.2018.03.012_bib0150","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.anai.2018.03.012_bib0155","series-title":"Encyclopedia of Research Design","first-page":"1566","article-title":"Tukey's honestly significant difference (hsd)","author":"Lane","year":"2010"},{"key":"10.1016\/j.anai.2018.03.012_bib0160","first-page":"889","article-title":"Measuring disease-specific quality of life in clinical trials","volume":"134","author":"Guyatt","year":"1986","journal-title":"CMAJ"},{"key":"10.1016\/j.anai.2018.03.012_bib0165","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/0895-4356(95)00054-2","article-title":"Relative responsiveness of condition-specific and generic health status measures in degenerative lumbar spinal stenosis","volume":"48","author":"Stucki","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.anai.2018.03.012_bib0170","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0895-4356(97)00097-8","article-title":"Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach","volume":"50","author":"Norman","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.anai.2018.03.012_bib0175","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0895-4356(03)00044-1","article-title":"Defining clinically meaningful change in health-related quality of life","volume":"56","author":"Crosby","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.anai.2018.03.012_bib0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.anai.2018.03.012_bib0185","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2500\/aap.2015.36.3873","article-title":"The minimal important difference for measures of urticaria disease activity: updated findings","volume":"36","author":"Mathias","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2018.03.012_bib0190","article-title":"The Urticaria Activity Score (UAS): validity, reliability and responsiveness [published online November 8, 2018]","author":"Hawro","year":"2017","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618302102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618302102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:19:55Z","timestamp":1761052795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618302102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1081120618302102"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.03.012","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validity and responsiveness of the Urticaria Activity and Impact Measure","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}